BIO.B

Bio-Rad LaboratoriesB

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$320.00

+5.2% vs current

Most likely

Base case

45%

Probability

Target price

$270.00

-11.2% vs current

B-

Bear case

30%

Probability

Target price

$220.00

-27.7% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

This remains a cautious monitoring memo because the starting packet had no primary notes, no recent-news set, and no social coverage, and the primary-source check mainly surfaced a weaker post-Q1 operating outlook rather than a clear reacceleration signal. Company evidence is solid enough to avoid a SERP-only view, but trusted analyst revision data after the April 30, 2026 print was not confirmed here, so the packet target should not be treated as strong corroboration. The May 8, 2026 anchor price of $255.54 also suggests the stock was still digesting the guide cut one week after results, keeping sentiment cautious rather than constructive [#PR-2026-04-30].

RankAlpha Sentiment Codex - 2026-05-09

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalyst2026 outlook reset is the main near-term sentiment driverHigh impact

Bio-Rad cut full-year 2026 non-GAAP currency-neutral revenue guidance to a range from down approximately 3.0% to up 0.5%, versus the prior 0.5% to 1.5% growth view, and cut expected non-GAAP operating margin to approximately 10.0% to 12.0% from approximately 12.0% to 12.5%; near-term trading likely depends on whether investors treat the reset as conservative enough after the first-quarter print [#PR-2026-04-30] [#PR-2026-02-12].

2026-09-30catalystCore demand stabilization must offset academic and Middle East headwindsHigh impact

First-quarter 2026 currency-neutral sales fell 4.3% in Life Science and 4.1% in Clinical Diagnostics, with management attributing pressure to ongoing academic research weakness in the Americas and conflict-driven disruption in the Middle East; evidence that these pressures are easing would matter more than the headline GAAP noise from Sartorius marks [#PR-2026-04-30] [#10Q-2026-05-01].

2026-12-31catalystddPCR and diagnostics execution is the main self-help offsetMedium impact

Management said Stilla Technologies has been successfully integrated with initial market adoption of the expanded ddPCR portfolio, while 2025 diagnostics execution included over 1,200 product registrations in more than 60 countries; the key longer-duration question is whether these self-help actions can improve mix enough to offset weak funding and regional disruptions [#PR-2026-02-12].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology